Ulf Grawunder
Director/Board Member at WUXI XDC CAYMAN INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Simon Jules Nebel | M | 58 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | 8 years |
| Peizhi Luo | M | 59 | 13 years | |
| Hans-Peter Gerber | M | 61 |
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.
T-CURX GmbH
| 5 years |
| Xiao Jie Xi | M | 49 | 1 years | |
| Fang Yong Du | M | 55 | 12 years | |
| Yiu Leung Cheung | M | 64 | 3 years | |
| Min Li | M | 62 | 3 years | |
| Stewart John Hen | M | 57 | - | |
| Man Kin Tam | M | 47 | 5 years | |
| Jin Cai Li | M | 51 | 4 years | |
| Jing Wei Zhang | M | 56 | 1 years | |
| Cuong Viet Do | M | 58 | 2 years | |
| Ami Knoefler | F | - | 3 years | |
| Mervyn Turner | M | 77 | 1 years | |
| Erich Schlick | M | 72 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
| Thomas Meier | M | 62 |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.
University of Basel
| 4 years |
| Songmao Zheng | M | - | 3 years | |
| Alexander Goergen | M | 38 | 7 years | |
| Chunfang Gu | F | - | 7 years | |
| Mei Ying Zhu | M | 59 | 1 years | |
| Ling Zhou | F | - | 5 years | |
| Dana Hu-Lowe | M | - | 3 years | |
| Ming Shi | F | 49 | 1 years | |
| Jens Hennecke | M | 56 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | - |
| Gui Zhong Liu | M | 54 | 9 years | |
| Qing Hai Zhao | M | 64 | 4 years | |
| JC Xu | M | 60 | 4 years | |
| Yumeng Wang | F | 33 | 1 years | |
| Wei Chang Zhou | M | 59 | 4 years | |
| Alan Tyndall | M | 76 |
University of Basel
| 33 years |
| Xiao Hong She | F | 58 | 13 years | |
| Detlev Mennerich | M | 55 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | - |
| Jiping Zha | M | - | 3 years | |
| Bertrand Damour | M | - |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
| Zhi Sheng Chen | M | 52 | 4 years | |
| Jian Jun Luo | M | 57 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrik Wettstein | M | 60 |
University of Basel
| 9 years |
| Rico Buchli | M | - |
University of Basel
| 8 years |
| Roland M. Müller | M | 61 |
University of Basel
| 6 years |
| Yan Li | F | 50 | 13 years | |
| Peter Kornicker | M | - |
University of Basel
| 6 years |
| Nicole Onetto | M | 71 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
| Christian Pfleger | M | 54 |
University of Bayreuth
| 6 years |
| Oliver M. Bartholet | M | 58 |
University of Basel
| 3 years |
| Jürgen Eckhardt | M | 57 |
University of Basel
| 3 years |
| Premal A. Desai | M | 55 |
University of Bayreuth
| 7 years |
| Carole Vischer | F | 53 |
University of Basel
| 3 years |
| Hans-Joachim König | M | 69 |
University of Bayreuth
| 4 years |
| Max P. Sommer | M | 92 |
University of Basel
| 3 years |
| Thomas Karger | M | - |
University of Basel
| - |
| Remy Hauser | M | 57 |
University of Basel
| 3 years |
| Theo H. Walthie | M | 76 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | - |
| Andreas C. Albrecht | M | 55 |
University of Basel
| 3 years |
| Jan Goepfert | M | 65 |
University of Basel
| 1 years |
| Beatrice Weder di Mauro | M | 57 |
University of Basel
| 3 years |
| Yannick Hausmann | M | 57 |
University of Basel
| 3 years |
| Michael Hüsler | M | 52 |
University of Basel
| 4 years |
| Markus Nauck | M | 59 |
University of Basel
| 3 years |
| Michael Claus Wisser | M | 52 |
University of Bayreuth
| 4 years |
| Mátyás Végh | M | - |
University of Basel
| 4 years |
| Matthias Schönberg | M | 57 |
University of Bayreuth
| 2 years |
| Dirk Haasner | M | 59 |
University of Basel
| 4 years |
| Robert von Vultejus | M | - |
University of Bayreuth
| 4 years |
| Ronald Roos | M | 56 |
University of Bayreuth
| 4 years |
| Michael Steib | M | - |
University of Bayreuth
| 2 years |
| Marc Oliver Heß | M | 51 |
University of Bayreuth
| 4 years |
| Jerome Pellaud | M | - |
University of Basel
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 29 | 43.28% |
| China | 20 | 29.85% |
| Germany | 10 | 14.93% |
| Cayman Islands | 9 | 13.43% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ulf Grawunder
- Personal Network
